Moneyview shares made a strong debut on the stock exchanges on Thursday, October 1, 2026, listing at a 61% premium to the IPO issue price on the NSE. The stock opened at ₹55 per share, compared with the issue price of ₹34. On the BSE, Moneyview shares started trading at ₹55.61, translating into a 63% premium.
The ₹1,091.68 crore IPO, which was open for bidding from September 24 to September 28, 2026, drew significant demand from investors. At the close of the subscription period, the issue had been subscribed 98.46 times.
Explore other Upcoming IPOs on BSE and NSE.
[September 28, 2026, 7:00 P.M.]
|
Category |
Subscription (x) |
|
Qualified Institutional Buyers (QIBs) |
227.45x |
|
Non-Institutional Investors (NIIs) |
115.41x |
|
Retail Individual Investors (RIIs) |
19.57X |
|
Total |
98.46x |
The company intends to utilise the net proceeds from the fresh issue towards:
Established in 2014, Moneyview Limited is a digital-first financial services platform serving consumers across Middle India. Its mobile app provides access to a range of financial products, including personal loans, credit cards, home loans, insurance, digital gold and UPI, through 48 Financial Partners, including its NBFC subsidiary, WFPL. As of June 30, 2026, the platform had 11.90 million monetized users and covered 99.04% of India’s pin codes.
Moneyview uses data, technology and AI/ML-based models to offer personalised financial products through a fully digital customer journey. Personal loans remain a key part of its business, with a Managed AUM of ₹225,201.65 million as of June 30, 2026. The company primarily serves digitally savvy middle-class consumers, with 79.54% of its monetized users located in Tier 2 and beyond cities.
|
Particulars |
FY26 (in ₹ crore) |
FY25 (in ₹ crore) |
FY24 (in ₹ crore) |
|
Total Income |
3,404.27 |
2,378.53 |
1,389.24 |
|
EBITDA |
968.92 |
697.98 |
328.70 |
|
Profit After Tax (PAT) |
242.71 |
240.28 |
171.15 |
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here